Send to

Choose Destination
J Thorac Dis. 2019 Sep;11(Suppl 15):S1963-S1965. doi: 10.21037/jtd.2019.07.80.

KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1-49.

Author information

Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO, USA.

Conflict of interest statement

Conflicts of Interest: Consultant fees: Abbvie, Bristol-Myers Squibb, PharmaMar and Takeda.

Supplemental Content

Full text links

Icon for AME Publishing Company Icon for PubMed Central
Loading ...
Support Center